Atlas Trials

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Clinical trial NCT03084939 · COMPLETED

Trial details

NCT number
NCT03084939
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2017-04-24
Primary completion
2018-11-23
Enrollment
351

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.